Northern Trust Corp Buys 142,578 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Northern Trust Corp raised its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 25.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 710,321 shares of the company's stock after purchasing an additional 142,578 shares during the period. Northern Trust Corp owned 1.32% of Fulcrum Therapeutics worth $3,339,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of FULC. Matisse Capital boosted its holdings in shares of Fulcrum Therapeutics by 20.4% in the 4th quarter. Matisse Capital now owns 128,445 shares of the company's stock valued at $604,000 after buying an additional 21,728 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Fulcrum Therapeutics by 2.3% during the fourth quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company's stock valued at $667,000 after purchasing an additional 3,126 shares in the last quarter. Bailard Inc. acquired a new position in shares of Fulcrum Therapeutics in the fourth quarter worth approximately $169,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Fulcrum Therapeutics by 176.8% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 367,594 shares of the company's stock valued at $1,728,000 after buying an additional 234,810 shares during the period. Finally, Intech Investment Management LLC lifted its stake in Fulcrum Therapeutics by 74.9% in the fourth quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock valued at $143,000 after buying an additional 13,057 shares during the period. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Price Performance

Fulcrum Therapeutics stock traded up $0.17 during midday trading on Thursday, hitting $7.07. 752,851 shares of the company were exchanged, compared to its average volume of 971,501. Fulcrum Therapeutics, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $10.13. The company's fifty day moving average price is $4.32 and its 200-day moving average price is $3.99. The company has a market cap of $381.63 million, a PE ratio of -22.81 and a beta of 2.29.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. On average, analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on FULC shares. Leerink Partnrs upgraded shares of Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 23rd. Cantor Fitzgerald raised shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price objective for the company in a report on Thursday, May 15th. Leerink Partners upgraded shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $4.00 to $12.00 in a research report on Friday, May 23rd. Piper Sandler reaffirmed an "overweight" rating and issued a $9.00 price target (up previously from $6.00) on shares of Fulcrum Therapeutics in a research note on Thursday. Finally, HC Wainwright restated a "neutral" rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Fulcrum Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $6.29.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.